MCID: DXR001
MIFTS: 39

Doxorubicin Induced Cardiomyopathy

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

MalaCards integrated aliases for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 53

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

MalaCards based summary : Doxorubicin Induced Cardiomyopathy is related to pulmonary blastoma and deafness, autosomal recessive 39. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and breast, and related phenotypes are Decreased cell migration and Decreased substrate adherent cell growth

Related Diseases for Doxorubicin Induced Cardiomyopathy

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to Doxorubicin Induced Cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.56 EGFR EPHB2 MAPK14 MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.33 EGFR EPHB2 MAPK14
3 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 MAPK14 MET
4 Increased cell viability after pRB stimulation GR00230-A-1 8.8 EGFR MAPK14 MET

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 CNR1 DES EGFR EPHB2 EPOR GATA4
2 cardiovascular system MP:0005385 10.15 DES ECE1 EGFR EPOR GATA4 HGF
3 growth/size/body region MP:0005378 10.13 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
4 embryo MP:0005380 10.05 ECE1 EGFR EPOR GATA4 HGF MAPK14
5 homeostasis/metabolism MP:0005376 10.03 CNR1 DES ECE1 EGFR EPOR GATA4
6 mortality/aging MP:0010768 10.02 CNR1 DES ECE1 EGFR EPHB2 EPOR
7 digestive/alimentary MP:0005381 10 CNR1 ECE1 EGFR EPHB2 GATA4 MET
8 hematopoietic system MP:0005397 10 CSF3 ECE1 EGFR EPOR GATA4 HGF
9 endocrine/exocrine gland MP:0005379 9.97 ECE1 EGFR EPHB2 GATA4 MAPK14 MET
10 integument MP:0010771 9.88 CNR1 CSF3 ECE1 EGFR GATA4 MAPK14
11 liver/biliary system MP:0005370 9.85 EGFR EPOR GATA4 HGF MAPK14 MET
12 nervous system MP:0003631 9.76 CNR1 ECE1 EGFR EPHB2 EPOR GATA4
13 muscle MP:0005369 9.73 DES ECE1 EGFR GATA4 MAPK14 MET
14 no phenotypic analysis MP:0003012 9.43 CNR1 EGFR EPOR GATA4 HGF MET
15 normal MP:0002873 9.17 CNR1 ECE1 EGFR EPOR GATA4 MAPK14

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Doxil Approved June 1999 Phase 2,Not Applicable 31703
5 Anti-Bacterial Agents Phase 2,Not Applicable
6 Antibiotics, Antitubercular Phase 2,Not Applicable
7 Topoisomerase Inhibitors Phase 2,Not Applicable
8 Albumin-Bound Paclitaxel Phase 2
9 Chelating Agents Not Applicable
10 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer Recruiting NCT02677714 Phase 2
2 Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients Unknown status NCT02078388 Doxorubicin
3 Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients Completed NCT03000036 Not Applicable Doxorubicin;Gadoterate Meglumine
4 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy Completed NCT02796365 Not Applicable
5 The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor Recruiting NCT03505164

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

Anatomical Context for Doxorubicin Induced Cardiomyopathy

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

41
Heart, Bone, Breast, Bone Marrow, Testes, Thyroid, Salivary Gland

Publications for Doxorubicin Induced Cardiomyopathy

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50) (show all 153)
# Title Authors Year
1
Cardiovascular variability and β-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy. ( 30342983 )
2019
2
Anti-oxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: Role of autophagy and c-kit<sup>pos</sup>CD45<sup>neg</sup>CD31<sup>neg</sup> cardiac stem cell activation. ( 29654879 )
2018
3
Ability of Nonstrain Diastolic Parameters to Predict Doxorubicin-Induced Cardiomyopathy: A Systematic Review With Meta-Analysis. ( 29045286 )
2018
4
Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium. ( 29146241 )
2018
5
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. ( 29074412 )
2018
6
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish. ( 29939187 )
2018
7
Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy. ( 29402309 )
2018
8
Localized Doxorubicin-Induced Cardiomyopathy Complicated With Shower Emboli Originating From Apical Intramural Thrombi. ( 29459534 )
2018
9
PTEN Inhibitor VO-OHpic Attenuates Inflammatory M1 Macrophages and Cardiac Remodeling in Doxorubicin-Induced Cardiomyopathy. ( 30095997 )
2018
10
Expression of Flk-1 and Cyclin D2 mRNA in the Myocardium of Rats with Doxorubicin-Induced Cardiomyopathy and after Treatment with Betulonic Acid Amide. ( 29063324 )
2017
11
Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. ( 28153388 )
2017
12
Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and AKT pathways. ( 28684738 )
2017
13
Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. ( 29026304 )
2017
14
Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy. ( 28662206 )
2017
15
Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. ( 28445944 )
2017
16
Correction to: &amp;quot;Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.&amp;quot; ( 28087848 )
2017
17
Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. ( 28608983 )
2017
18
Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. ( 28423723 )
2017
19
Vitamin C mitigates oxidative/nitrosative stress and inflammation in Doxorubicin-induced cardiomyopathy. ( 28710069 )
2017
20
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. ( 26873966 )
2016
21
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. ( 27167338 )
2016
22
Sarco&amp;quot;MiR&amp;quot; friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. ( 27294099 )
2016
23
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. ( 27087047 )
2016
24
Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. ( 27261628 )
2016
25
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. ( 26511374 )
2015
26
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. ( 25938766 )
2015
27
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. ( 26885153 )
2015
28
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. ( 25660617 )
2015
29
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. ( 25590792 )
2015
30
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. ( 26191652 )
2015
31
Heart rate dynamics in doxorubicin-induced cardiomyopathy. ( 25798626 )
2015
32
Shengmai injection improved Doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. ( 25839043 )
2015
33
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. ( 25569804 )
2015
34
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. ( 26057572 )
2015
35
Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. ( 26075032 )
2015
36
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. ( 25504881 )
2014
37
Embryonic Stem Cells and Released Factors Stimulate c-kit (+ve) /FLK-1(+ve) Progenitor Cells and Promote Neovascularization in Doxorubicin-induced Cardiomyopathy. ( 24593859 )
2014
38
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice. ( 25263201 )
2014
39
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. ( 25298583 )
2014
40
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. ( 24486195 )
2014
41
Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. ( 24767791 )
2014
42
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. ( 24338479 )
2013
43
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. ( 23741376 )
2013
44
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. ( 24334905 )
2013
45
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. ( 24244825 )
2013
46
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. ( 23731918 )
2013
47
Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats. ( 24343415 )
2013
48
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. ( 24228260 )
2013
49
Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. ( 22719160 )
2012
50
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. ( 22465037 )
2012

Variations for Doxorubicin Induced Cardiomyopathy

Expression for Doxorubicin Induced Cardiomyopathy

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for Doxorubicin Induced Cardiomyopathy

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 CSF3 DES EGFR EPHB2 EPOR HGF
2
Show member pathways
13.51 EGFR EPHB2 EPOR GATA4 HGF MAPK14
3
Show member pathways
13.37 EGFR EPHB2 EPOR HGF MAPK14 MET
4
Show member pathways
13.35 EGFR EPHB2 EPOR HGF MAPK14 MET
5
Show member pathways
13.2 CSF3 ECE1 EGFR EPHB2 EPOR HGF
6
Show member pathways
13.15 EGFR EPHB2 EPOR HGF MET
7
Show member pathways
13.06 CSF3 EGFR EPHB2 EPOR HGF MAPK14
8
Show member pathways
13.04 EGFR EPHB2 EPOR HGF MAPK14 MET
9
Show member pathways
12.86 EGFR EPHB2 HGF MAPK14 MET
10
Show member pathways
12.79 EGFR EPHB2 EPOR MAPK14 MET
11
Show member pathways
12.79 CSF3 EGFR EPOR HGF MET
12
Show member pathways
12.74 EGFR HGF MAPK14 MET
13
Show member pathways
12.7 EGFR EPOR GATA4 MAPK14
14 12.66 EGFR EPOR HGF MET
15
Show member pathways
12.6 EGFR HGF MAPK14 MET
16 12.59 EGFR HGF MAPK14 MET
17
Show member pathways
12.44 CNR1 EGFR HGF MAPK14 MET
18
Show member pathways
12.2 HGF MAPK14 MET
19 12.1 EGFR HGF MAPK14 MET
20 11.96 EGFR EPHB2 MET
21 11.9 GATA4 HGF MET
22 11.9 EGFR HGF MET
23
Show member pathways
11.9 EGFR HGF MAPK14 MET
24
Show member pathways
11.73 EGFR EPHB2 EPOR HGF MAPK14 MET
25
Show member pathways
11.71 EGFR HGF MET
26 11.34 CSF3 HGF MET
27
Show member pathways
11.26 EGFR HGF MET
28 11.21 EGFR EPOR GATA4 MAPK14
29 11.21 EGFR HGF MET
30 11.15 EGFR MET
31 11.09 EGFR EPOR
32 11.06 CSF3 HGF MAPK14
33 11.04 GATA4 MAPK14
34 11.03 EGFR HGF MET
35 10.84 HGF MET
36 10.81 EGFR HGF MET
37 10.07 CSF3 DES EGFR EPHB2 EPOR HGF

GO Terms for Doxorubicin Induced Cardiomyopathy

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CSF3 EGFR EPHB2 EPOR HGF MAPK14
2 basal plasma membrane GO:0009925 9.16 EGFR MET
3 receptor complex GO:0043235 9.13 EGFR EPHB2 MET

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 CSF3 EGFR GATA4 HGF MAPK14 MET
2 protein phosphorylation GO:0006468 9.87 EGFR EPHB2 MAPK14 MET
3 negative regulation of apoptotic process GO:0043066 9.86 EGFR EPHB2 HGF MET
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 EGFR EPHB2 MET
5 heart development GO:0007507 9.75 ECE1 EPOR GATA4
6 positive regulation of MAPK cascade GO:0043410 9.71 EGFR EPHB2 MET
7 MAPK cascade GO:0000165 9.71 EGFR HGF MAPK14 MET
8 negative regulation of signal transduction GO:0009968 9.7 EGFR EPHB2 MET
9 phosphatidylinositol phosphorylation GO:0046854 9.69 EGFR HGF MET
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 EGFR EPHB2 MET
11 liver development GO:0001889 9.63 EGFR HGF MET
12 axonal fasciculation GO:0007413 9.55 CNR1 EPHB2
13 learning or memory GO:0007611 9.54 CNR1 EGFR EPHB2
14 hepatocyte growth factor receptor signaling pathway GO:0048012 9.49 HGF MET
15 peptidyl-tyrosine phosphorylation GO:0018108 9.46 EGFR EPHB2 HGF MET
16 negative regulation of autophagy GO:0010507 9.43 GATA4 HGF MET
17 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.32 HGF MET
18 positive regulation of protein kinase B signaling GO:0051897 9.26 CSF3 EGFR HGF MET
19 cell morphogenesis GO:0000902 8.92 EGFR EPHB2 HGF MAPK14

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.78 EGFR EPHB2 MAPK14 MET
2 protein kinase activity GO:0004672 9.73 EGFR EPHB2 MAPK14 MET
3 transmembrane signaling receptor activity GO:0004888 9.63 EGFR EPHB2 MET
4 identical protein binding GO:0042802 9.63 DES EGFR EPHB2 EPOR HGF MET
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGFR HGF MET
6 protein phosphatase binding GO:0019903 9.54 EGFR MAPK14 MET
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR HGF MET
8 NFAT protein binding GO:0051525 9.26 GATA4 MAPK14
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 MET
10 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHB2 HGF MET

Sources for Doxorubicin Induced Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....